Hyperphosphatemia in patients with ESRD: Assessing the current evidence linking outcomes with treatment adherence

BMC Nephrology

Volumn 14, Issue 1, 2013, Pages

  Covic, Adrian ^a,b   Rastogi, Anjay ^c  

^a GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b CI Parhon Hospital   (Romania)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adherence; Chronic kidney disease; Hyperphosphatemia; Phosphate binder; Pill burden

Indexed keywords

ALUMINUM SALT; CALCIUM ACETATE; CALCIUM CARBONATE; LANTHANUM CARBONATE; MAGNESIUM CARBONATE; PHOSPHATE; PHOSPHATE BINDING AGENT; PHOSPHORUS; SEVELAMER; SEVELAMER CARBONATE;

APPETITE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; DIABETES MELLITUS; DIET RESTRICTION; DRUG EFFECT; EDUCATIONAL STATUS; EVIDENCE BASED MEDICINE; FOLLOW UP; HEMODIALYSIS PATIENT; HUMAN; HYPERPHOSPHATEMIA; HYPERTENSION; KIDNEY DYSFUNCTION; KIDNEY FAILURE; MEDICATION COMPLIANCE; MINERAL METABOLISM; MORTALITY; NUTRITIONAL STATUS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT EDUCATION; PHOSPHATE BLOOD LEVEL; PHOSPHATE INTAKE; PHOSPHATE METABOLISM; PRACTICE GUIDELINE; PROTEIN INTAKE; REVIEW; SELF MONITORING; SOCIAL STATUS; TELECONSULTATION;

HUMANS; HYPERPHOSPHATEMIA; KIDNEY FAILURE, CHRONIC; PATIENT COMPLIANCE; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 84880181442     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-14-153     Document Type: Review

References (68)

1. Phosphate metabolism in the setting of chronic kidney disease: significance and recommendations for treatment. Kestenbaum B, Semin Dial 2007 20 4 286 294
2. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM, J Am Soc Nephrol JASN 2004 15 8 2208 2218 (Pubitemid 39031360)
3. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. Slinin Y, Foley RN, Collins AJ, J Am Soc Nephrol JASN 2005 16 6 1788 1793 (Pubitemid 41716485)
4. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kalantar-Zadeh K, Kuwae N, Regidor DL, Kovesdy CP, Kilpatrick RD, Shinaberger CS, McAllister CJ, Budoff MJ, Salusky IB, Kopple JD, Kidney Int 2006 70 4 771 780 (Pubitemid 44215354)
5. Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. Covic A, Kothawala P, Bernal M, Robbins S, Chalian A, Goldsmith D, Nephrol Dial Transplant 2009 24 5 1506 1523
6. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, Young EW, Akizawa T, Akiba T, Pisoni RL, et al. Am J Kidney Dis 2008 52 3 519 530
7. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. Gutiérrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Juppner H, et al. N Engl J Med 2008 359 6 584 592
8. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Floege J, Kim J, Ireland E, Chazot C, Drueke T, de Francisco A, Kronenberg F, Marcelli D, Passlick-Deetjen J, Schernthaner G, et al. Nephrol Dial Transplant 2011 26 6 1948 1955
9. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group: Kidney Int Suppl 2009 113 1 130
10. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. National Kidney Foundation, Am J Kidney Dis 2003 42 4 Suppl 3 1 201
11. Improving CKD-MBD management in haemodialysis patients: barrier analysis for implementing better practice. Toussaint ND, Pedagogos E, Beavis J, Becker GJ, Polkinghorne KR, Kerr PG, Nephrol Dial Transplant 2011 26 4 1319 1326
12. Improving outcomes for dialysis patients in the international dialysis outcomes and practice patterns study. Port FK, Pisoni RL, Bommer J, Locatelli F, Jadoul M, Eknoyan G, Kurokawa K, Canaud BJ, Finley MP, Young EW, Clin J Am Soc Nephrol 2006 1 2 246 255
13. Association of dietary phosphorus intake and phosphorus to protein ratio with mortality in hemodialysis patients. Noori N, Kalantar-Zadeh K, Kovesdy CP, Bross R, Benner D, Kopple JD, Clin J Am Soc Nephrol 2010 5 4 683 692
14. Management of natural and added dietary phosphorus burden in kidney disease. Cupisti A, Kalantar-Zadeh K, Semin Nephrol 2013 33 2 180 190
15. EBPG guideline on nutrition. Fouque D, Vennegoor M, ter Wee P, Wanner C, Basci A, Canaud B, Haage P, Konner K, Kooman J, Martin-Malo A, et al. Nephrol Dial Transplant 2007 22 Suppl 2 i45 87
16. Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease? Shinaberger CS, Greenland S, Kopple JD, Van Wyck D, Mehrotra R, Kovesdy CP, Kalantar-Zadeh K, Am J Clin Nutr 2008 88 6 1511 1518
17. Nutrition and chronic kidney disease. Fouque D, Pelletier S, Mafra D, Chauveau P, Kidney Int 2011 80 4 348 357
18. Prescribed dietary phosphate restriction and survival among hemodialysis patients. Lynch KE, Lynch R, Curhan GC, Brunelli SM, Clin J Am Soc Nephrol 2011 6 3 620 629
19. Prevention and control of phosphate retention/hyperphosphatemia in CKD-MBD: what is normal, when to start, and how to treat? Martin KJ, Gonzalez EA, Clin J Am Soc Nephrol 2011 6 2 440 446
20. Phosphorus additives in food and their effect in dialysis patients. Uribarri J, Clin J Am Soc Nephrol 2009 4 8 1290 1292
21. Extra-phosphate load from food additives in commonly eaten foods: a real and insidious danger for renal patients. Benini O, D'Alessandro C, Gianfaldoni D, Cupisti A, J Ren Nutr 2011 21 4 303 308
22. Oral phosphate binders in patients with kidney failure. Tonelli M, Pannu N, Manns B, N Engl J Med 2010 362 14 1312 1324
23. Dietary phosphorus restriction in advanced chronic kidney disease: merits, challenges, and emerging strategies. Gutierrez OM, Wolf M, Semin Dial 2010 23 4 401 406
24. Comparison of dietary phosphate absorption after single doses of lanthanum carbonate and sevelamer carbonate in healthy volunteers: a balance study. Martin P, Wang P, Robinson A, Poole L, Dragone J, Smyth M, Pratt R, Am J Kidney Dis 2011 57 5 700 706
25. Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden. Hutchison AJ, Laville M, Graup S-LS, Nephrol Dial Transplant 2008 23 11 3677 3684
26. Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate. Hutchison AJ, Maes B, Vanwalleghem J, Asmus G, Mohamed E, Schmieder R, Backs W, Jamar R, Vosskuhler A, Nephron Clin Pract 2005 100 1 8 19
27. Pharmacology, efficacy and safety of oral phosphate binders. Hutchison AJ, Smith CP, Brenchley PE, Nat Rev Nephrol 2011 7 10 578 589
28. Lanthanum carbonate. Joy MS, Kshirsagar A, Candiani C, Brooks T, Hudson JQ, Ann Pharmacother 2006 40 2 234 240 (Pubitemid 43269853)
29. Phosphate binders for preventing and treating bone disease in chronic kidney disease patients. Navaneethan SD, Palmer SC, Vecchio M, Craig JC, Elder GJ, Strippoli GF, Cochrane Database Syst Rev 2011 2 D006023
30. Considerations about the effectiveness and cost effectiveness of therapies in the treatment of hyperphosphataemia. Plagemann T, Prenzler A, Mittendorf T, Health Econ Rev 2011 1 1 1
31. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate. Sprague SM, Curr Med Res Opin 2007 23 12 3167 3175
32. Phosphorus binders and survival on hemodialysis. Isakova T, Gutierrez OM, Chang Y, Shah A, Tamez H, Smith K, Thadhani R, Wolf M, J Am Soc Nephrol 2009 20 2 388 396
33. Outcomes associated with phosphorus binders in men with non-dialysis-dependent CKD. Kovesdy CP, Kuchmak O, Lu JL, Kalantar-Zadeh K, Am J Kidney Dis 2010 56 5 842 851
34. Phosphate Binder Use and Mortality Among Hemodialysis Patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS): Evaluation of Possible Confounding by Nutritional Status. Lopes AA, Tong L, Thumma J, Li Y, Fuller DS, Morgenstern H, Bommer J, Kerr PG, Tentori F, Akiba T, et al. Am J Kidney Dis 2012 60 1 90 101
35. Phosex® Summary of Product Characteristics Pharmacosmos A/S, Holbaek, Denmark. Available at: http://www.medicines.org.uk/emc/medicine/14132. Last revised: October 2011. Accessed: 15 July 2013
36. Calcichew Summary of Product Characteristics Shire Pharmaceuticals Ltd., Basingstoke, United Kingdom. Available at: http://www.medicines.org.uk/emc/ medicine/1987/SPC/Calcichew+500mg+Chewable+Tablets/. Last revised: June 2010. Accessed: 15 July 2013
37. Renvela® (sevelamer carbonate). Prescribing Information 2011 Available from: http://www.renvela.com/~/media/RenvelaUS/Files/RV382-Renvela-PI- 08.2011.pdf. Last revised: May 2011. Accessed: 15 July 2013
38. Phosphate binders, cardiovascular calcifications and mortality: do we need another survival study with sevelamer? Negri AL, J Nephrol 2010 23 6 653 657
39. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Suki WN, Zabaneh R, Cangiano JL, Reed J, Fischer D, Garrett L, Ling BN, Chasan-Taber S, Dillon MA, Blair AT, et al. Kidney Int 2007 72 9 1130 1137 (Pubitemid 47609037)
40. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Block GA, Spiegel DM, Ehrlich J, Mehta R, Lindbergh J, Dreisbach A, Raggi P, Kidney Int 2005 68 4 1815 1824 (Pubitemid 43169927)
41. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM, Kidney Int 2007 71 5 438 441
42. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Chertow GM, Burke SK, Raggi P, Group TTtGW, Kidney Int 2002 62 1 245 252 (Pubitemid 34754068)
43. The case against calcium-based phosphate binders. Moe SM, Chertow GM, Clin J Am Soc Nephrol 2006 1 4 697 703
44. Effects of Phosphate Binders in Moderate CKD. Block GA, Wheeler DC, Persky MS, Kestenbaum B, Ketteler M, Spiegel DM, Allison MA, Asplin J, Smits G, Hoofnagle AN, et al. J American Society Nephrol 2012 23 8 1407 1415
45. Adherence to prescribed oral medication in adult patients undergoing chronic hemodialysis: a critical review of the literature. Schmid H, Hartmann B, Schiffl H, Eur J Med Res 2009 14 5 185 190
46. A meta-analysis of the association between adherence to drug therapy and mortality. Simpson SH, Eurich DT, Majumdar SR, Padwal RS, Tsuyuki RT, Varney J, Johnson JA, BMJ 2006 333 7557 15
47. Skipped treatments, markers of nutritional nonadherence, and survival among incident hemodialysis patients. Unruh ML, Evans IV, Fink NE, Powe NR, Meyer KB, Study CfHOiCfE-SRDC, Am J Kidney Dis 2005 46 6 1107 1116 (Pubitemid 41690237)
48. Challenge of phosphorus control in hemodialysis patients: a problem of adherence? Arenas MD, Malek T, Gil MT, Moledous A, Álvarez-Ude F, Reig-Ferrer A, J Nephrol 2010 23 5 525 534
49. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Chiu YW, Teitelbaum I, Misra M, de Leon EM, Adzize T, Mehrotra R, Clin J Am Soc Nephrol 2009 4 6 1089 1096
50. A systematic review of the prevalence and determinants of nonadherence to phosphate binding medication in patients with end-stage renal disease. Karamanidou C, Clatworthy J, Weinman J, Horne R, BMC Nephrol 2008 9 2
51. Pill burden in HIV infection: 20 years of experience. Krentz HB, Cosman I, Lee K, Ming JM, Gill MJ, Antivir Ther 2012 17 5 833 840
52. Importance of medication adherence in cardiovascular disease and the value of once-daily treatment regimens. Frishman WH, Cardiol Rev 2007 15 5 257 263 (Pubitemid 47282034)
53. Medication prescribing patterns in ambulatory haemodialysis patients: comparisons of USRDS to a large not-for-profit dialysis provider. Manley HJ, Garvin CG, Drayer DK, Reid GM, Bender WL, Neufeld TK, Hebbar S, Muther RS, Nephrol Dial Transplant 2004 19 7 1842 1848 (Pubitemid 38961397)
54. A randomized, parallel, open-label study to compare once-daily sevelamer carbonate powder dosing with thrice-daily sevelamer hydrochloride tablet dosing in CKD patients on hemodialysis. Fishbane S, Delmez J, Suki WN, Hariachar SK, Heaton J, Chasan-Taber S, Plone MA, Moe S, Am J Kidney Dis 2010 55 2 307 315
55. Assessment of pharmacodynamic equivalence and tolerability of lanthanum carbonate oral powder and tablet formulations: a single-center, randomized, open-label, 2-period crossover study in healthy subjects. Pierce D, Hossack S, Robinson A, Zhang P, Martin P, Clin Ther 2012 34 6 1290 1300 e2
56. Cognitive impairment in the aging dialysis and chronic kidney disease populations: an occult burden. Murray AM, Adv Chronic Kidney Dis 2008 15 2 123 132 (Pubitemid 351343871)
57. Phosphate binders, KDOQI guidelines and compliance: the unfortunate reality. Tomasello S, Dhupar S, Sherman RA, Dial Transplant 2004 33 5 236 242
58. Interventions for enhancing medication adherence. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X, Cochrane Database Syst Rev 2008 2 D000011
59. A randomized controlled trial of an educational intervention to improve phosphate levels in hemodialysis patients. Ashurst Ide B, Dobbie H, J Ren Nutr 2003 13 4 267 274 (Pubitemid 38367740)
60. Education for dialysis patients lowers long-term phosphate levels and maintains health-related quality of life. Gardulf A, Pålsson M, Nicolay U, Graup SRN, Clin Nephrol 2011 75 4 319 327
61. Nurse-led education and counselling to enhance adherence to phosphate binders. Van Camp YP, Huybrechts SA, Van Rompaey B, Elseviers MM, J Clin Nurs 2012 21 9-10 1304 1313
62. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. Lee JK, Grace KA, Taylor AJ, JAMA 2006 296 21 2563 2571 (Pubitemid 44903860)
63. Thinking outside the pillbox-medication adherence as a priority for health care reform. Cutler DM, Everett W, N Engl J Med 2010 362 17 1553 1555
64. Management of hyperphosphatemia. Kuhlmann MK, Hemodial Int 2006 10 4 338 345 (Pubitemid 44489916)
65. Self-adjustment of phosphate binder dose to meal phosphorus content improves management of hyperphosphataemia in children with chronic kidney disease. Ahlenstiel T, Pape L, Ehrich JH, Kuhlmann MK, Nephrol Dial Transplant 2010 25 10 3241 3249
66. A preference study: calcium acetate tablets versus gelcaps in hemodialysis patients. Kaplan MR, Stashenko CL, Bledsoe AL, McGowan J, Nephrol Nurs J 2002 29 4 363 365
67. Higher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: a multicenter study. Mehrotra R, Martin KJ, Fishbane S, Sprague SM, Zeig S, Anger M, Fosrenol Overview Research Evaluation Study for Early Experience Study G, Clin J Am Soc Nephrol 2008 3 5 1437 1445
68. Pharmacotherapy of chronic kidney disease and mineral bone disorder. Barreto FC, de Oliveira RA, Oliveira RB, Jorgetti V, Expert Opin Pharmacother 2011 12 17 2627 2640